New drug tested for Tough-to-Treat stomach and digestive cancers
NCT ID NCT05628857
Summary
This study tested an experimental drug called RC108 in patients with advanced cancers of the digestive system, such as stomach, colon, liver, or pancreatic cancer, whose tumors had a specific marker called c-Met. The main goals were to see if the drug could shrink tumors, how safe it was, and how it moved through the body. It involved 29 participants and was an open-label Phase 2 trial, meaning everyone knew they were receiving the study drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hopspital
Beijing, Beijing Municipality, 000000, China
Conditions
Explore the condition pages connected to this study.